BAX BAXTER INTERNATIONAL INC — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$22.21

Period return

+2.14 (+10.66%)

Volume

3.1M

2026-07-21O $21.86 H $22.24 L $21.84 C $22.21MA5 $22.48MA20 $22.08MA60 $19.78MA120 $19.24

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 07. 30.Highin 9 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 29.MediumSELL2 months ago
Citigroup: Sell
US analyst rating / recommendation change.
2026. 05. 04.LowBUY3 months ago
Barclays: Overweight
US analyst rating / recommendation change.
2026. 04. 07.LowBUY4 months ago
Evercore ISI Group: Outperform
US analyst rating / recommendation change.
2026. 03. 12.LowHOLD4 months ago
Citigroup: Neutral
US analyst rating / recommendation change.
2026. 02. 18.LowHOLD5 months ago
Goldman Sachs: Neutral
US analyst rating / recommendation change.
2026. 02. 14.LowBUY5 months ago
Barclays: Overweight
US analyst rating / recommendation change.
2026. 01. 09.LowBUY6 months ago
Barclays: Overweight
US analyst rating / recommendation change.
2025. 12. 03.LowSELL8 months ago
Morgan Stanley: Underweight
US analyst rating / recommendation change.
2025. 11. 01.LowHOLD9 months ago
Citigroup: Neutral
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $21.96 · 13 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Sector: Healthcare
Industry

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 07. 30.	After market close (AMC)	$0.37	—	—	$2.8B	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$0.25	—	—	$2.63B	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-0.27	—	—	$7.88B	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$-0.54	—	—	$5.18B	Reported

BAXTER INTERNATIONAL INC

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 29.	Citigroup	—	Downgrade	Neutral → Sell	—	Citigroup: Neutral → Sell
2026. 05. 04.	Barclays	—	Maintain	Overweight → Overweight	—	Barclays: Overweight
2026. 04. 07.	Evercore ISI Group	—	Maintain	Outperform → Outperform	—	Evercore ISI Group: Outperform
2026. 03. 12.	Citigroup	—	Maintain	Neutral → Neutral	—	Citigroup: Neutral
2026. 02. 18.	Goldman Sachs	—	Maintain	Neutral → Neutral	—	Goldman Sachs: Neutral
2026. 02. 14.	Barclays	—	Maintain	Overweight → Overweight	—	Barclays: Overweight